Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 01/17 10:00:00 pm
102.02 USD   -2.67%
01/17 CELGENE : Juno Therapautics Pops on Word of Buyout by Celgene
01/17 JUNO THERAPEUTI : up on Celgene takeout rumors
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene : to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017-7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 01:35pm CET

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will alsohost a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

View source version on businesswire.com : http://www.businesswire.com/news/home/20171002005698/en/

Celgene Corporation
Patrick E. Flanigan III, 908-673-9969
Corporate VP, Investor Relations
orBrian Gill, 908-673-9530
VP, Corporate Communications

Source: Celgene Corporation

News Provided by Acquire Media

Celgene Corporation published this content on 02 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 October 2017 11:34:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
01/17 CELGENE : Juno Therapautics Pops on Word of Buyout by Celgene
01/17 JUNO THERAPEUTICS : up on Celgene takeout rumors
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/14 Drug innovations helping cancer patients worldwide
01/10 CELGENE : J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact Bio..
01/10 CELGENE : expects 2018 growth as it moves past setbacks that cratered shares
01/09 U.S. pharma executives expect deals to pick up after tax overhaul
01/09 CELGENE : buys cancer therapy maker Impact Biomedicines for $1.1B
More news
News from SeekingAlpha
01/17 HEALTHCARE : The 'Week That Was' Was Good
01/17 Celgene slips 2% premarket on potential Juno takeout
01/17 Juno rally spreads to bluebird and Cellectis
01/17 WALL STREET BREAKFAST : Investors Ready For Fed-Filled Day
01/17 POLEN CAPITAL : Portfolio Manager Commentary Q4 2017
Financials ($)
Sales 2017 12 978 M
EBIT 2017 7 488 M
Net income 2017 4 448 M
Debt 2017 4 449 M
Yield 2017 -
P/E ratio 2017 18,79
P/E ratio 2018 14,69
EV / Sales 2017 6,70x
EV / Sales 2018 5,53x
Capitalization 82 527 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 124 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION1.57%82 527
JOHNSON & JOHNSON4.32%394 542
NOVARTIS1.41%227 089
PFIZER0.88%218 162
ROCHE HOLDING LTD.-4.26%211 361
MERCK AND COMPANY10.31%169 287